Ketamine Research and Policy Updates
News and research summaries focused on what changes in evidence, regulation, access, and clinical practice may mean for ketamine patients and providers.
What belongs here
Current research, policy, FDA, DEA, trial, and access updates with patient-facing context and links to primary sources when available.
What to read next
Use news articles for context, then move to the evergreen guide or safety hub for durable treatment planning information.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
Featured
3 articlesNew Study Shows IV Ketamine Beats Nasal Esketamine
Recent research reveals IV ketamine achieves higher remission rates than nasal esketamine for depression treatment. What this means for patients.
Psychiatrist Outlines Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at major psychiatric conference. Key insights for treatment seekers.
Boston Clinics Spotlight Ketamine's Growing Role in Mental Health
Boston clinics are expanding ketamine therapy for mental health. What patients should know about access, cost, and what to expect from treatment.
New Study Shows IV Ketamine Beats Nasal Esketamine
Recent research reveals IV ketamine achieves higher remission rates than nasal esketamine for depression treatment. What this means for patients.
Psychiatrist Outlines Key Ketamine Patient Considerations
Dr. Benjamin Brody highlights critical patient considerations for ketamine treatment at major psychiatric conference. Key insights for treatment seekers.
Boston Clinics Spotlight Ketamine's Growing Role in Mental Health
Boston clinics are expanding ketamine therapy for mental health. What patients should know about access, cost, and what to expect from treatment.
Is Ketamine the Future of Mental Health Treatment?
A local news segment spotlights ketamine therapy's growing role in mental health. Here's what the coverage gets right — and what patients should know.
Psych Deprescribing Debate: What It Means for Ketamine
HHS targets psychiatric overprescribing. Experts say stop what's not working—and replace it with evidence-based alternatives. Here's how ketamine fits in.
CBT After Esketamine Cuts Relapse Risk, Trial Finds
The CBT-ENDURE trial found that pairing esketamine with 16 weeks of CBT reduced suicidal ideation and depression severity better than esketamine alone.
Schizophrenia Survey Reveals Gaps That Echo Across Psychiatry
A new SPAN survey exposes persistent care gaps in schizophrenia treatment. Here's why those findings matter across the broader psychiatric landscape.
Faster TRD Remission: Why Measurement-Based Care Matters
New clinical guidance on TRD emphasizes fast dose adjustments and symptom tracking—here's what it means for patients considering ketamine therapy.
Ketamine Side Effects: What the Data Says on Dropout
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients and providers set realistic expectations for ketamine treatment.
Faster TRD Remission: What Smarter Dosing Means for You
New guidance on treatment-resistant depression stresses faster dose adjustments and symptom tracking. Here's what it means for ketamine therapy patients.
Ketamine Side Effects: What the Data Now Shows
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives ketamine patients a clearer picture of what to expect and when to switch.
Ketamine vs. Esketamine: Side Effects and Who Stops Treatment
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients make smarter choices about ketamine-based depression treatment.
Ketamine Side Effects: What the Data Says in 2026
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients and providers make smarter decisions about ketamine treatment.
Faster TRD Remission: What Measurement-Based Care Means
New guidance on treatment-resistant depression emphasizes faster dose adjustment and symptom tracking—here's why it matters for ketamine patients.
Smarter TRD Care Gets Patients to Remission Faster
New psychiatric guidance on TRD highlights how symptom tracking and dose adjustment speed remission—here's what it means for ketamine patients.
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
New clinical thinking on treatment-resistant depression urges aggressive care aimed at full remission — not just symptom reduction. Here's what it means for patients.
Faster TRD Remission: What Better Protocols Mean for You
New guidance on TRD treatment highlights faster dose adjustment and symptom tracking. Here's what it means for patients considering ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission—here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.
Esketamine's Role in Treatment-Resistant Depression
Esketamine (Spravato) for treatment-resistant depression: how it works, who qualifies, REMS clinic visits, cost ranges, and Spravato vs IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BXCL501 Enters Phase 2a Trial for Acute Stress & PTSD
A new DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions. Here's what it means for the evolving PTSD treatment landscape.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Ketamine Compounding Regulations in 2026: What Has Changed
An overview of the latest regulatory developments affecting compounded ketamine in 2026, including FDA enforcement updates, state-level changes, and the impact on patient access.
DEA Telehealth Prescribing Rules: What Changed in 2025
DEA telehealth prescribing rules for controlled substances in 2025: Ryan Haight extensions, in-person visit triggers, and what they mean for ketamine access.
Ketamine Clinic Safety Standards: What Patients Should Expect
An overview of emerging safety standards for ketamine treatment clinics, including clinical protocols, monitoring requirements, provider qualifications, and what patients should look for when evaluating a ketamine provider.
Compounding Pharmacies and Ketamine: What Patients Should Know
What patients should know about compounding pharmacies that prepare ketamine formulations, including quality standards, regulatory oversight, and how to choose a pharmacy.
State-Level Ketamine Therapy Regulations: 2025 Landscape
State-by-state ketamine therapy rules for 2025: telehealth prescribing, in-person visit triggers, supervision, and compounding limits — what changed and where.
The Rise of At-Home Ketamine Treatment Companies
Major at-home ketamine therapy companies compared by dose, monitoring, published outcomes, and pricing — and the safety questions to ask before you enroll.
Key Ketamine Research Developments in 2025
Ketamine research highlights from 2025: TRD trials, BPL-003 phase 2a, measurement-based care data, telehealth outcomes, and what shifted in clinical practice.
FDA Esketamine (Spravato) Updates
A summary of the latest FDA regulatory actions, label updates, and clinical developments related to esketamine (Spravato) for depression treatment.
Ketamine Insurance Coverage: 2025 Trends and Developments
Ketamine insurance coverage in 2025: Spravato payer trends, off-label IV claim outcomes, prior-auth patterns, and what coverage gaps patients still face.
Telehealth Ketamine: Evolving Regulations
Telehealth ketamine prescribing rules in 2025: DEA Ryan Haight extensions, in-person visit triggers, dose limits, and the state variations patients hit.
International Ketamine Research: Global Developments and Discoveries
A roundup of significant ketamine research from around the world, including clinical trials, regulatory developments, and scientific discoveries outside the United States.